biote バランスシートの健全性
財務の健全性 基準チェック /26
bioteの総株主資本は$-48.0M 、総負債は$105.7Mで、負債比率は-220.4%となります。総資産と総負債はそれぞれ$89.0Mと$137.0Mです。 bioteの EBIT は$30.3Mで、利息カバレッジ比率3です。現金および短期投資は$5.3Mです。
主要情報
-220.36%
負債資本比率
US$105.68m
負債
| インタレスト・カバレッジ・レシオ | 3x |
| 現金 | US$5.32m |
| エクイティ | -US$47.95m |
| 負債合計 | US$136.99m |
| 総資産 | US$89.03m |
財務の健全性に関する最新情報
Recent updates
ナラティブ更新 • Jul 16
BTMD: Index Removal And Buybacks Will Support 2026 Recovery Potential
Analysts have lowered their fair value estimate for biote from $4.00 to $3.43, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. What’s in the News for biote biote Corp.
ナラティブ更新 • Jun 22
BTMD: New Interim Leadership And 2026 Outlook Will Support Earnings Upside
Analysts have trimmed their price target on biote by $1, citing updated assumptions around discount rates and forward P/E, while keeping fair value and long term growth expectations broadly in line with prior views. What's in the News for biote biote reaffirmed full year 2026 earnings guidance, maintaining an outlook for revenue above $190 million.ナラティブ更新 • Jun 05
BTMD: Recall Resolution And Higher Spending Will Support Later Earnings Upside
Narrative Update: Biote Analysts have trimmed their average price targets for Biote by around $1, reflecting recent research that points to mixed signals from Q4 results, a lower FY26 outlook after the voluntary recall and higher investment plans, as well as progress on sales force and platform initiatives that could support improved profitability and a lower future P/E assumption. Analyst Commentary Recent research highlights a mix of optimism and caution around Biote, with analysts adjusting price targets lower in response to Q4 results, updated FY26 guidance and ongoing investment plans.ナラティブ更新 • May 19
BTMD: Recall And Investment Reset Will Support 2026 Revenue Recovery Potential
Analysts have trimmed their average price targets for biote to a lower range, generally cutting expectations by about $1 per share as they factor in the impact of a voluntary recall, higher planned investment and a slower pace of new clinic growth before a potential sales recovery in 2026. Analyst Commentary Across recent research, bullish analysts have adjusted their models to reflect the recall, higher planned spending, and a slower clinic ramp, yet many still see room for value creation if management executes on its plan through 2026.ナラティブ更新 • May 02
BTMD: Recall Disruption And Higher Investment Spend Will Set Up Later Upside
Narrative Update Analysts have trimmed the average price target for biote by about $0.20 as they factor in a lower fair value estimate, a higher assumed future P/E, and recent research pointing to recall related pressures, increased investment plans, and mixed clinic growth trends. Analyst Commentary Recent research updates on biote point to a mixed setup, with analysts weighing near term recall and investment headwinds against execution on sales initiatives and clinic growth potential.ナラティブ更新 • Apr 17
BTMD: Recall Resolution And Clinic Productivity Investments Will Support Future Upside
The average analyst price target on biote has been reduced to about $4 from roughly $6, as analysts factor in lower forecast revenue growth, slimmer projected profit margins, a higher discount rate, and a much higher assumed future P/E multiple following recent guidance updates and the impacts of the product recall. Analyst Commentary Recent Street research reflects a reset in expectations, but it also highlights areas where bullish analysts still see room for value creation if biote executes on its plans and manages the recall process effectively.ナラティブ更新 • Apr 03
BTMD: Affordable Medicines Theme Will Support Upside As Investments Settle
Analysts have trimmed biote's average price target as firms reset expectations to a lower range of $2 to $5, citing the impact of a voluntary recall, higher operating investments, and slower clinic growth, even as they acknowledge progress on sales execution and systems upgrades. Analyst Commentary Recent research highlights a reset in expectations around biote, with lower price targets reflecting near term operational and growth headwinds, alongside recognition of execution progress and investments aimed at future expansion.
ナラティブ更新 • Mar 20
BTMD: Affordable Medicines Theme Will Support Upside As 2026 Plan Advances
Analysts have trimmed the consolidated price target for biote to a range of about $2 to $3. This reflects more cautious assumptions on growth and profitability following guidance tied to the voluntary recall, higher investment, and slower clinic expansion.ナラティブ更新 • Mar 06
BTMD: Affordable Medicines Theme Will Drive Upside Despite Recent Cautious Reassessment
Analysts recently trimmed their 12 month price target on biote to $5 from $6, with the change tied to updated views on discount rates, revenue growth potential, profit margins, and a slightly higher assumed future P/E multiple, while still citing the broader affordable medicines theme as a key part of the thesis heading into 2026. Analyst Commentary Recent Street research has highlighted a more cautious tone around biote, with the 12 month price target trimmed to $5 from $6.ナラティブ更新 • Feb 20
BTMD: Affordable Medicines Theme Will Support Upside Case Despite Lower Street Expectations
Analysts have trimmed their price target on biote to $5 from $6, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E. They continue to highlight the company’s fit within the broader affordable medicines theme.ナラティブ更新 • Feb 05
BTMD: Affordable Medicines Theme Will Support Upside Potential Despite Lowered Expectations
Narrative update on biote Analysts have trimmed their price target on biote to US$5 from US$6, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions, while still highlighting affordable medicines as a supportive theme heading into 2026. Analyst Commentary Recent research reflects a more cautious stance on biote's share price while still pointing to the affordable medicines theme as an important support for the story heading into 2026.ナラティブ更新 • Jan 22
BTMD: Affordable Medicines Theme Will Support Reassessed Outlook Into 2026
Analysts recently trimmed their price target on biote to $5 from $6, citing a mix of updated assumptions on fair value, discount rate, growth, margins, and future P/E expectations as they reassessed the stock within the broader affordable medicines theme heading into 2026. Analyst Commentary Recent Street research on Biote has focused on recalibrating expectations around valuation, execution, and growth, with some Bearish analysts taking a more cautious stance even as the broader affordable medicines theme remains in focus heading into 2026.ナラティブ更新 • Jan 07
BTMD: Affordable Medicines Theme And Buybacks Will Support Upside Potential
Analysts have trimmed their price target on biote to $5 from $6, citing a still supportive view on the affordable medicines theme, even as they fine tune assumptions for revenue growth, margins, and future P/E expectations. Analyst Commentary Even with the trimmed price target, bullish analysts continue to frame biote within the affordable medicines theme, suggesting they still see room for the shares to reflect that positioning over time.ナラティブ更新 • Dec 13
BTMD: Share Repurchases Will Support Future Upside In This Bullish Outlook
Analysts have modestly raised their price target on biote to reflect stronger expected revenue growth and a higher future earnings multiple, partially offset by more conservative margin and discount rate assumptions. What's in the News biote Corp.Seeking Alpha • Sep 10
Restructuring At Biote Will Drive Greater Growth And Profitability
Summary I maintain my Strong Buy rating on biote Corp. due to its promising growth prospects, despite ongoing restructuring and short-term earnings pressure. The company’s vertical integration, digital platform growth, and improved cost controls are driving margin expansion and long-term profitability potential. Restructuring aims to accelerate provider wins, deepen practitioner relationships, and boost financial discipline, though it has led to lower 2025 guidance. Valuation remains attractive with significant upside to intrinsic value, but investors should monitor debt levels, potential dilution, and execution risks. Read the full article on Seeking Alpha分析記事 • Aug 09
Results: biote Corp. Exceeded Expectations And The Consensus Has Updated Its Estimates
One of the biggest stories of last week was how biote Corp. ( NASDAQ:BTMD ) shares plunged 26% in the week since its...ナラティブ更新 • Aug 08
Commercial Reorganization And E-Commerce Expansion Will Drive Mixed Future Prospects
The significant drop in biote’s net profit margin combined with a sharply higher future P/E suggests deteriorating profitability and a less attractive valuation outlook, leading to the consensus analyst price target being revised down from $6.40 to $4.98. What's in the News Biote Corp.分析記事 • Aug 08
Benign Growth For biote Corp. (NASDAQ:BTMD) Underpins Stock's 28% Plummet
NasdaqGM:BTMD 1 Year Share Price vs Fair Value Explore biote's Fair Values from the Community and select yours biote...分析記事 • May 10
biote Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
biote Corp. ( NASDAQ:BTMD ) investors will be delighted, with the company turning in some strong numbers with its...分析記事 • May 09
Market Participants Recognise biote Corp.'s (NASDAQ:BTMD) Earnings
With a price-to-earnings (or "P/E") ratio of 37.3x biote Corp. ( NASDAQ:BTMD ) may be sending very bearish signals at...分析記事 • Dec 02
biote Corp. (NASDAQ:BTMD) Soars 26% But It's A Story Of Risk Vs Reward
biote Corp. ( NASDAQ:BTMD ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...分析記事 • Sep 27
Market Cool On biote Corp.'s (NASDAQ:BTMD) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 0.9x biote Corp. ( NASDAQ:BTMD ) is definitely a stock...
新しいナラティブ • Sep 26
Biote's Innovative Strategies And Expansions Set To Enhance Revenue And Shareholder Value
Expanding the practitioner network and launching BioteRx aim to uniquely position the company in the wellness market, possibly boosting revenue through differentiated service offerings.Seeking Alpha • Sep 27
biote initiated as a buy at Truist on leadership in hormone optimization; sees 138% upside
Truist has initiated biote Corp. (NASDAQ:BTMD) with a buy rating highlighting the company's leadership in providing bioidentical hormone replacement therapy to improve hormonal imbalance. The firm has a $10 price target (~138% upside based on Monday's close). Analyst Gregory Fraser said that the company's platform "provides physicians with effective treatment options as well as a source of income" and added that the model has led to revenue and EBITDA growth. He noted that biote's (BTMD) growth strategy is focused on increasing utlilization of both existing and new partner clinics. Truist conducted a survey of 25 physicians who use biote's (BTMD) bioidentical hormone replacement therapy and found they expect to prescribe more of the company's pellet therapy over the next year. Seeking Alpha's Quant Rating views biote (BTMD) as a strong buy.Seeking Alpha • Sep 07
Biote partners with IMAC Holdings
biote Corp (NASDAQ:BTMD) said it had entered into a partnership with IMAC Holdings, to add the latter's services to its network of outpatient clinics that deliver orthopedic, regenerative, and advanced, non-surgical medical procedures. The Company said it had begun training IMAC medical professionals in the Biote Method for launching the treatments at select IMAC Regeneration Centers in September. "We are excited to add Biote’s services to IMAC clinics, which will be used to implement innovative weight loss and hormone optimization therapy within our current patient population," said Jeff Ervin, IMAC Founder and Chief Executive Officer. IMAC Holdings deliver sports medicine, orthopedic care, and restorative joint and tissue therapies for movement restricting pain and neurodegenerative diseases.財務状況分析
短期負債: BTMDは マイナスの株主資本 を有しており、これは 短期資産 が 短期負債 をカバーしていないことよりも深刻な状況です。
長期負債: BTMDは株主資本がマイナスであり、これは短期資産が 長期負債 をカバーしていないことよりも深刻な状況です。
デット・ツー・エクイティの歴史と分析
負債レベル: BTMDは 株主資本がマイナス となっており、これは高い負債レベルよりも深刻な状況です。
負債の削減: BTMDの株主資本はマイナスなので、時間の経過とともに負債が減少したかどうかを確認する必要はありません。
債務返済能力: BTMDの負債は 営業キャッシュフロー によって 十分にカバー されています ( 30.9% )。
インタレストカバレッジ: BTMDの負債に対する 利息支払い は EBIT ( 3 x coverage) によって 十分にカバーされています。
貸借対照表
健全な企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/21 21:21 |
| 終値 | 2026/07/21 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
biote Corp. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6
| アナリスト | 機関 |
|---|---|
| Jeffrey Van Sinderen | B. Riley Securities, Inc. |
| Kaumil Gajrawala | Jefferies LLC |
| George Kelly | Roth Capital Partners |